Published in Cancer Res on March 15, 2008
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther (2009) 2.08
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am J Pathol (2010) 1.16
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 1.15
The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis (2010) 1.07
Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol (2009) 1.05
Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. Neuro Oncol (2009) 1.01
Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One (2013) 0.99
PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. Neuro Oncol (2010) 0.99
PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Cancer Biol Ther (2009) 0.95
Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ (2014) 0.95
Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther (2009) 0.95
An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem (2010) 0.94
Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets (2014) 0.93
PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation. Carcinogenesis (2010) 0.91
A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. Neoplasia (2013) 0.85
Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. Front Oncol (2016) 0.84
Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy. Mol Cancer Ther (2011) 0.84
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Oncogene (2016) 0.83
Applications of emerging molecular technologies in glioblastoma multiforme. Expert Rev Neurother (2008) 0.83
Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status. PLoS One (2014) 0.82
Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs. J Ovarian Res (2013) 0.78
Personalized characterization of diseases using sample-specific networks. Nucleic Acids Res (2016) 0.76
PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression. Cell Cycle (2014) 0.75
Surfing the p53 network. Nature (2000) 35.36
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Regulation of PTEN transcription by p53. Mol Cell (2001) 5.44
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Gain of function mutations in p53. Nat Genet (1993) 4.19
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res (2000) 3.30
The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res (1998) 3.15
The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci (2002) 2.37
p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03
Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol (1998) 1.85
PTEN and p53: who will get the upper hand? Cancer Cell (2003) 1.84
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene (2001) 1.80
Transcription regulation by mutant p53. Oncogene (2007) 1.78
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene (2006) 1.78
Tumours and tremors: how PTEN regulation underlies both. Br J Cancer (2006) 1.70
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem (2001) 1.66
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst (1999) 1.44
The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res (2005) 1.35
Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem (2004) 1.27
PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem (2004) 1.25
Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res (2000) 1.21
PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res (2006) 1.19
Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene (1997) 1.11
Mutant p53 proteins: between loss and gain of function. Head Neck (2007) 1.09
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene (2004) 1.07
Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J Neurochem (2001) 1.02
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther (2007) 1.01
Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. Cancer Res (1999) 0.93
The expression of both domains of the 69/71 kDa 2',5' oligoadenylate synthetase generates a catalytically active enzyme and mediates an anti-viral response. Eur J Biochem (1999) 0.87
PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors. Am J Obstet Gynecol (2003) 0.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Forecasting the global burden of Alzheimer's disease. Alzheimers Dement (2007) 10.01
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med (2003) 4.57
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci (2003) 3.77
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med (2010) 3.62
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med (2008) 2.93
Malignant spinal-cord compression. Lancet Oncol (2005) 2.71
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
New physician-investigators receiving National Institutes of Health research project grants: a historical perspective on the "endangered species". JAMA (2007) 2.59
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30
Global health development assistance remained steady in 2013 but did not align with recipients' disease burden. Health Aff (Millwood) (2014) 2.26
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol (2005) 2.24
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Whole body cooling in newborn infants with perinatal asphyxial encephalopathy in a low resource setting: a feasibility trial. Indian Pediatr (2010) 2.13
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther (2009) 2.08
Neuromuscular complications of cancer diagnosis and treatment. J Support Oncol (2005) 2.06
Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer (2010) 2.06
The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer (2002) 1.98
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg (2009) 1.91
microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle (2010) 1.90
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement (2008) 1.89
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med (2010) 1.81
Nutrient reference values for bioactives: new approaches needed? A conference report. Eur J Nutr (2013) 1.76
c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A (2011) 1.75
Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol (2004) 1.71
Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. NMR Biomed (2008) 1.70
ppGpp: stringent response and survival. J Microbiol (2006) 1.66
Apolipoprotein E polymorphisms and severity of cerebral palsy: a cross-sectional study in 255 children in Norway. Dev Med Child Neurol (2013) 1.66
Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle Nerve (2008) 1.66
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a. Proc Natl Acad Sci U S A (2009) 1.64
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res (2012) 1.58
In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J (2001) 1.55
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2009) 1.55
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res (2006) 1.54
Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med (2012) 1.54
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol (2006) 1.53
Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res (2009) 1.52
Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine. J Neurosci (2003) 1.51
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
Upregulation of IL-6, IL-8, CXCL1, and CXCL2 dominates gene expression in human fibroblast cells exposed to Loxosceles reclusa sphingomyelinase D: insights into spider venom dermonecrosis. J Invest Dermatol (2006) 1.48
Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol (2009) 1.48
Loss of the DNA methyltransferase MET1 Induces H3K9 hypermethylation at PcG target genes and redistribution of H3K27 trimethylation to transposons in Arabidopsis thaliana. PLoS Genet (2012) 1.48
ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res (2007) 1.45
Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother (2011) 1.45
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2006) 1.44
KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer (2006) 1.44
Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol (2010) 1.43
Mammalian gut immunity. Biomed J (2014) 1.43
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother (2008) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
BosR (BB0647) governs virulence expression in Borrelia burgdorferi. Mol Microbiol (2009) 1.42
Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant. Oncology (Williston Park) (2008) 1.42
Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res (2005) 1.42
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. J Neurosurg (2011) 1.42
Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci U S A (2003) 1.41
Neurologic complications of chemotherapy agents. Curr Opin Neurol (2007) 1.39
Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res (2008) 1.37
Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J (2014) 1.37
Tracing the factors responsible for arsenic enrichment in groundwater of the middle Gangetic Plain, India: a source identification perspective. Environ Geochem Health (2009) 1.37
The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res (2005) 1.35
Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab (2010) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34